UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ________ TO ________ COMMISSION FILE NUMBER: 001-40738 WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 RENOVORX, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 27-1448452 (State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________ FORM 10-Q __________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ________ TO ________ COMMISSION FILE NUMBER: 001-40738 RENOVORX, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHAR ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Commission File Number: 001-40738 RENOVORX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 27-1448452 (I.R.S. Employer Identification No.) 4546 El Camino Real, Suite B1, Los Altos, CA 94022 (Address of principal executive offices, including zip code) (650) 284-4433 (Registrant's telephone number, including area code) Securities registered purs ...

Clinical Trials and Research - RenovoRx has completed Phase 1/2 studies in locally advanced pancreatic cancer, showing a median overall survival rate of 27.9 months compared to the historical control of 12-15 months[112] - RenovoGem is currently being evaluated in a Phase 3 registration IND clinical trial, with interim data expected in the second half of 2022[112] - RenovoRx plans to expand its clinical trials, including a planned trial for hilar cholangiocarcinoma (HCCA) and potentially other indications[112] - The ongoing COVID-19 pandemic has negatively impacted clinical studies, including challenges in recruiting subjects for trials[119] - Clinical trial expenses are accrued based on estimates from service providers regarding work performed, including patient enrollment and study completion[162] Financial Performance - As of September 30, 2021, RenovoRx reported cash and cash equivalents of $17.7 million and an accumulated deficit of $18.9 million[114] - The company incurred net losses of $1.5 million and $4.0 million for the three and nine months ended September 30, 2021, respectively[114] - The net loss for the three months ended September 30, 2021 was $1.5 million, representing a 38% increase from a net loss of $1.1 million in the prior year[135] - The net loss for the nine months ended September 30, 2021 was $4.0 million, a 36% increase from a net loss of $2.9 million in the prior year[141] - Cash used in operating activities for the nine months ended September 30, 2021 was $4.0 million, compared to $2.9 million for the same period in 2020, reflecting a 38% increase in net loss[155] Operating Expenses - For the three months ended September 30, 2021, total operating expenses increased by 53% to $1.4 million compared to $0.9 million in the same period of 2020[135] - Research and development expenses for the three months ended September 30, 2021 were $0.8 million, a 6% increase from $0.7 million in the prior year quarter[136] - General and administrative expenses surged by 243% to $0.6 million for the three months ended September 30, 2021, compared to $0.2 million in the same period of 2020[137] - For the nine months ended September 30, 2021, total operating expenses rose by 29% to $3.3 million compared to $2.6 million in the same period of 2020[141] - The company expects to continue incurring significant operating losses and negative cash flows from operations for the foreseeable future[114] - The company expects to incur additional losses and increased operating expenses in future periods[148] Funding and Capital Structure - RenovoRx completed its IPO in August 2021, raising gross proceeds of $16.7 million, with net proceeds of $14.6 million after deducting underwriting discounts and expenses[113] - Net cash provided by financing activities for the nine months ended September 30, 2021 was $19.3 million, a significant increase from $2.7 million in the same period of 2020, representing a 615% increase[157] - As of September 30, 2021, the company had no contractual obligations or other commitments, with $5.3 million in convertible notes converted to common shares upon IPO completion[158] Company Status and Outlook - The company is classified as an "emerging growth company" and will remain so until the earlier of December 31, 2026, or achieving total annual gross revenues of at least $1.07 billion[170] - The company has not generated any revenue from product sales and does not expect to do so for several years[121] - The company has not experienced any material impact from inflation on its business, financial condition, or results of operations during the nine months ended September 30, 2021[180] Interest and Currency Management - Interest expense, net for the nine months ended September 30, 2021 was $0.8 million, a 135% increase from $0.4 million in the same period of 2020[144] - The fair value of cash and cash equivalents would not be significantly affected by interest rate changes, as the interest rates for the 2020 and 2021 Convertible Notes were fixed[178] - The company has not engaged in hedging foreign currency transactions to date but may evaluate the costs and benefits of such a program in the future[179] Stock-Based Compensation - Stock-based compensation is recognized over a vesting period of generally four years, with fair value calculated using the Black-Scholes option pricing model[163] Off-Balance Sheet Arrangements - The company had no off-balance sheet arrangements during the periods presented[175]